Efficacy and tolerability of indiplon in transient insomnia

Journal of Clinical Sleep Medicine

Volumn 3, Issue 4, 2007, Pages 374-379

  Rosenberg, Russell ^a   Roth, Thomas ^b   Scharf, Martin B ^c   Lankford, D Alan ^d   Farber, Robert ^e  

^a The Atlanta Snoring and Sleep Disorders Institute   (United States)

^b HENRY FORD HOSPITAL   (United States)

^c Tri State Sleep Disorders Center   (United States)

^d Sleep Disorders Center of Georgia   (United States)

^e NEUROCRINE BIOSCIENCES INC   (United States)

Author keywords

Hypnotic; Indiplon; Insomnia

Indexed keywords

INDIPLON; PLACEBO;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAM; EPWORTH SLEEPINESS SCALE; FEMALE; HEADACHE; HUMAN; INSOMNIA; LABORATORY TEST; MALE; NAUSEA; NORMAL HUMAN; POLYSOMNOGRAPHY; RANDOMIZED CONTROLLED TRIAL; REM SLEEP; SLEEP PARAMETERS; SLEEP PATTERN; SLEEP TIME; SOMNOLENCE; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 34250832201     PISSN: 15509389     EISSN: 15509397     Source Type: Journal    
DOI: 10.5664/jcsm.26859     Document Type: Article

References (21)

1. Leger D, Guilleminault C, Dreyfus JP, Delahaye C, Paillard M. Prevalence of insomnia in a survey of 12,778 adults in France. J Sleep Res 2000;9:35-42.
2. Ohayon M, Epidemiological study of insomnia in the general population. Sleep 1996;19(3 Suppl):S7-15.
3. Ohayon MM, Caulet M, Guilleminault C. Complaints about nocturnal sleep: how a general population perceives its sleep, and how this relates to the complaint of insomnia. Sleep 1997;20:715-23.
4. Bonnet MH, Arand DL. Situational insomnia: consistency, predictors, and outcomes. Sleep 2003;26:1029-36.
5. Roth T, Roehrs T. Insomnia: epidemiology, characteristics, and consequences. Clin Cornerstone 2003;5:5-15.
6. Roth T, Hajak G, Ustun TB. Consensus for the pharmacological management of insomnia in the new millennium. Int J Clin Pract 2001;55:42-52.
7. Drake C, Richardson G, Roehrs T, Scofield H, Roth T. Vulnerability to stress-related sleep disturbance and hyperarousal. Sleep 2004;27:285-91.
8. Agnew HW Jr, Webb WB, Williams RL. The first night effect: an EEG study of sleep. Psychophysiology 1966;2:263-6.
9. Roehrs T, Vogel G, Sterling W, Roth T. Dose effects of temazepam in transient insomnia. Arzneimittelforschung 1990;40:859-62.
10. Vogel G. Clinical uses and advantages of low doses of benzodiazepine hypnotics. J Clin Psychiatry 1992;53:19-22.
11. Roth T, Roehrs T, Vogel G. Zolpidem in the treatment of transient insomnia: a double-blind, randomized comparison with placebo. Sleep 1995;18:246-51.
12. Erman MK, Loewy D, Scharf MB. Comparison of temazepam 7.5 mg with temazepam 15 mg for the treatment of transient insomnia. Curr Med Res Opin 2004;20:441-9.
13. Walsh JK, Schweitzer PK, Sugerman JL, Muehlbach MJ. Transient insomnia associated with a 3-hour phase advance of sleep time and treatment with zolpidem. J Clin Psychopharmacol 1990;10:184-9.
14. Erman MK, Erwin CW, Gengo FM, et al. Comparative efficacy of zolpidem and temazepam in transient insomnia. Hum Psychopharmacol 2001;16:169-76.
15. Walsh JK, Benca RM, Bonnet M. National Heart, Lung, and Blood Institute Working Group on Insomnia. Insomnia: assessment and management in primary care. Am Fam Physician 1999;59:3029-39.
16. Rechtschaffen A, Kales A. A manual of standardized terminology techniques and scoring system for sleep stages of human subjects. Washington DC; US Government Printing Office, National Institute of Health Publication No. 204;1968
17. Scharf M, Rosenberg R, Cohn M, Zammit GK, Jochelson P. Efficacy and safety of indiplon in elderly patients with chronic insomnia. Poster presentation at annual American Psychiatric Association meeting, New York, NY, May, 2004.
18. Walsh JK, Roth T, Lankford DA, Rosenberg R, Jochelson P. Efficacy and safety of 35 days of treatment with indiplon in adults with chronic insomnia. Poster presentation at annual American Psychiatric Association meeting, New York, NY, May, 2004.
19. Garber M, Burke J, Farber R, Jochelson P. Residual effects of middle of the night dosing: a placebo-controlled crossover study of indiplon, zolpidem, and zopiclone in healthy volunteers. Poster presentation at annual American Psychiatric Association meeting, New York, NY, May, 2004.
20. Feinberg I, Fein G, Walker JM, Price LJ, Floyd TC, March JD. Flurazepam effects on slow-wave sleep: stage 4 suppressed but number of delta waves constant. Science 1977;198:847-8.
21. Bixler EO, Kales A, Soldatos CR, Scharf MB, Kales JD. Effectiveness of temazepam with short-intermediate-, and long-term use: sleep laboratory evaluation. J Clin Pharmacol 1978;18:110-18.